A comprehensive review of dysregulated mirnas involved in cervical cancer

Current Genomics

Volumn 15, Issue 4, 2014, Pages 310-323

  Sharma, Garima ^a   Dua, Pradeep ^b   Agarwal, Subhash Mohan ^a  

^a INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^b Central Council for Research in Ayurvedic Sciences (CCRAS)   (India)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; MiRNA; MiRNA cluster; MiRNA targets

Indexed keywords

MICRORNA; TRANSCRIPTION FACTOR;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CHEMOSENSITIVITY; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER;

EID: 84923133403     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202915666140528003249     Document Type: Article

References (163)

1. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 1993, 75, 843-854.
2. Farazi, T.A.; Hoell, J.I.; Morozov, P.; Tuschl, T. MicroRNAs in human cancer.Adv. Exp. Med. Biol., 2013, 774, 1-20.
3. Zhang, B.; Pan, X.; Cobb, G.P.; Anderson, T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol., 2007, 302, 1-12.
4. Iorio, M.V.; Croce, C.M. Causes and consequences of microRNA dysregulation. Cancer J., 2012, 18, 215-222.
5. Agarwal, S.M.; Raghav, D.; Singh, H.; Raghava, G.P. CCDB: a curated database of genes involved in cervix cancer. Nucleic Acids Res., 2011, 39, D975-979.
6. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA. Cancer J. Clin., 2011, 61, 69-90.
7. Park, T.W.; Fujiwara, H.; Wright, T.C. Molecular biology of cervi- cal cancer and its precursors. Cancer, 1995, 76, 1902-1913.
8. Wilting, S.M.; de Wilde, J.; Meijer, C.J.; Berkhof, J.; Yi, Y.; van Wieringen, W.N.; Braakhuis, B.J.; Meijer, G.A.; Ylstra, B.; Snijders, P.J. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer, 2008, 47, 890-905.
9. Reshmi, G.; Pillai, M.R. Beyond HPV: oncomirs as new players in cervical cancer. FEBS Lett., 2008, 582, 4113-4116.
10. Zheng, Z.-M.; Wang, X. Regulation of cellular miRNA expression by human papillomaviruses. Biochim. Biophys. Acta, Gene Regul. Mech., 2011, 1809, 668-677.
11. Zhang, L.; Huang, J.; Yang, N.; Greshock, J.; Megraw, M.S.; Giannakakis, A.; Liang, S.; Naylor, T.L.; Barchetti, A.; Ward, M.R. microRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 9136-9141.
12. Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 15524-15529.
13. Aqeilan, R.; Calin, G.; Croce, C. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ., 2010, 17, 215-220.
14. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 2999-3004.
15. Caramazza, D.; Hussein, K.; Siragusa, S.; Pardanani, A.; Knudson, R.A.; Ketterling, R.P.; Tefferi, A. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype–phenotype associations. Eur. J. Haematol., 2010, 84, 191-200.
16. Wilting, S.M.; Steenbergen, R.D.; Tijssen, M.; van Wieringen, W.N.; Helmerhorst, T.J.; van Kemenade, F.J.; Bleeker, M.C.; van de Wiel, M.A.; Carvalho, B.; Meijer, G.A. Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. Cancer Res., 2009, 69, 647-655.
17. Cheung, T.H.; Chung, H.; Kwok, T.; Poon, C.S.; Hampton, G.M.; Wang, V.W.; Wong, Y.F. Allelic loss on chromosome 1 is associated with tumor progression of cervical carcinoma. Cancer, 1999, 86, 1294-1298.
18. Bulten, J.; Melchers, W.J.; Kooy-Smits, M.M.; de Wilde, P.; Poddighe, P.J.; Robben, J.; Macville, M.V.; Massuger, L.F.; Bakkers, J.M.; Hanselaar, A.G. Numerical aberrations of chromosome 1 in cervical intraepithelial neoplasia are strongly associated with infection with high-risk human papillomavirus types. J. Pathol., 2002, 198, 300-309.
19. Cheung, T.-H.; Lo, K.W.-K.; Yim, S.-F.; Poon, C.-s.; Cheung, A.Y.-K.; Chung, T.K.-H.; Wong, Y.-F. Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer. Gynecol. Oncol., 2005, 96, 510-515.
20. Debacker, K.; Kooy, R.F. Fragile sites and human disease. Hum. Mol. Genet., 2007, 16, R150-R158.
21. Wang, J.; Tai, L.-S.; Tzang, C.-H.; Fong, W.F.; Guan, X.-Y.; Yang, M. 1p31, 7q21 and 18q21 chromosomal aberrations and candidate genes in acquired vinblastine resistance of human cervical carcinoma KB cells. Oncol. Rep., 2008, 19, 1155-1164.
22. Seitz, S.; Poppe, K.; Fischer, J.; Nothnagel, A.; Estévez-Schwarz, L.; Haensch, W.; Schlag, P.M.; Scherneck, S. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J. Pathol., 2001, 194, 318-326.
23. Farrand, K.; Delahunt, B.; Wang, X.-l.; McIver, B.; Hay, I.D.; Goellner, J.R.; Eberhardt, N.L.; Grebe, S.K. High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene. J. Clin. Endocrinol. Metab., 2002, 87, 4715-4721.
24. Huang, J.; Hu, N.; Goldstein, A.M.; Emmert-Buck, M.R.; Tang, Z.- Z.; Roth, M.J.; Wang, Q.-H.; Dawsey, S.M.; Han, X.-Y.; Ding, T. High frequency allelic loss on chromosome 17p13. 3–p11. 1 in esophageal squamous cell carcinomas from a high incidence area in northern China. Carcinogenesis, 2000, 21, 2019-2026.
25. Olaharski, A.J.; Sotelo, R.; Solorza-Luna, G.; Gonsebatt, M.E.; Guzman, P.; Mohar, A.; Eastmond, D.A. Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis, 2006, 27, 337-343.
26. Herrington, C.; Worsham, M.; Southern, S.; Mackowiak, P.; Wolman, S. Loss of sequences on the short arm of chromosome 17 is a late event in squamous carcinoma of the cervix. Mol. Pathol., 2001, 54, 160-164.
27. Miyai, K.; Furugen, Y.; Matsumoto, T.; Iwabuchi, K.; Hirose, S.; Kinoshita, K.; Fujii, H. Loss of heterozygosity analysis in uterine cervical adenocarcinoma. Gynecol. Oncol., 2004, 94, 115-120.
28. Kuuselo, R.; Simon, R.; Karhu, R.; Tennstedt, P.; Marx, A.H.; Izbicki, J.R.; Yekebas, E.; Sauter, G.; Kallioniemi, A. 19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes Cancer, 2010, 49, 569-575.
29. Kawakami, T.; Zhang, C.; Taniguchi, T.; Kim, C.J.; Okada, Y.; Sugihara, H.; Hattori, T.; Reeve, A.E.; Ogawa, O.; Okamoto, K. Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene, 2004, 23, 6163-6169.
30. Benoît, M.-H.; Hudson, T.J.; Maire, G.; Squire, J.A.; Arcand, S.L.; Provencher, D.; Mes-Masson, A.-M.; Tonin, P.N. Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. Int. J. Oncol., 2007, 30, 5-17.
31. Weakley, S.M.; Wang, H.; Yao, Q.; Chen, C. Expression and function of a large non-coding RNA gene XIST in human cancer. World J. Surg., 2011, 35, 1751-1756.
32. Edelmann, J.; Richter, K.; Hänel, C.; Hering, S.; HORN, L.C. X chromosomal and autosomal loss of heterozygosity and microsatellite instability in human cervical carcinoma. Int. J. Gynecol. Cancer, 2006, 16, 1248-1253.
33. Hopman, A.H.; Smedts, F.; Dignef, W.; Ummelen, M.; Sonke, G.; Mravunac, M.; Vooijs, G.P.; Speel, E.J.M.; Ramaekers, F. Transition of high-grade cervical intraepithelial neoplasia to microinvasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J. Pathol., 2004, 202, 23-33.
34. Dellas, A.; Torhorst, J.; Gaudenz, R.; Mihatsch, M.J.; Moch, H. DNA copy number changes in cervical adenocarcinoma. Clin. Cancer Res., 2003, 9, 2985-2991.
35. Marzano, R.; Corrado, G.; Merola, R.; Sbiroli, C.; Guadagni, F.; Vizza, E.; Del Nonno, F.; Carosi, M.; Galati M.M.; Sperduti, I. Analysis of chromosomes 3, 7, X and the EGFR gene in uterine cervical cancer progression. Eur. J. Cancer, 2004, 40, 1624-1629.
36. Nakopoulou, L.; Panayotopoulou, E.G.; Giannopoulou, I.; Tsirmpa, I.; Katsarou, S.; Mylona, E.; Alexandrou, P.; Keramopoulos, A. Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis. J. Clin. Pathol., 2007, 60, 808-815.
37. Lin, S.-L.; Miller, J.D.; Ying, S.-Y. Intronic MicroRNA (miRNA). J. Biomed. Biotechnol., 2006, 2006, 26818.
38. Rodriguez, A.; Griffiths-Jones, S.; Ashurst, J.L.; Bradley, A. Identification of mammalian microRNA host genes and transcription units. Genome Res., 2004, 14, 1902-1910.
39. Cullen, B.R. Transcription and processing of human microRNA precursors. Mol. Cell, 2004, 16, 861-865.
40. Monteys, A.M.; Spengler, R.M.; Wan, J.; Tecedor, L.; Lennox, K.A.; Xing, Y.; Davidson, B.L. Structure and activity of putative intronic miRNA promoters. RNA, 2010, 16, 495-505.
41. Farazi, T.A.; Hoell, J.I.; Morozov, P.; Tuschl, T. miRNAs in human cancer. Adv. Exp. Med. Biol., 2013, 774, 1-20.
42. He, L.; Thomson, J.M.; Hemann, M.T.; Hernando-Monge, E.; Mu, D.; Goodson, S.; Powers, S.; Cordon-Cardo, C.; Lowe, S.W.; Hannon, G.J. A microRNA polycistron as a potential human oncogene. Nature, 2005, 435, 828-833.
43. Cai, N.; Wang, Y.-D.; Zheng, P.-S. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA, 2013, 19, 85-95.
44. Wilting, S.; Snijders, P.; Verlaat, W.; Jaspers, A.; Van De Wiel, M.; Van Wieringen, W.; Meijer, G.; Kenter, G.; Yi, Y.; le Sage, C. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene, 2013, 32, 106-116.
45. Lee, J.-W.; Choi, C.H.; Choi, J.-J.; Park, Y.-A.; Kim, S.-J.; Hwang, S.Y.; Kim, W.Y.; Kim, T.-J.; Lee, J.-H.; Kim, B.-G.; Bae, D.-S. Altered MicroRNA expression in cervical carcinomas. Clin. Cancer Res., 2008, 14, 2535-2542.
46. Witten, D.; Tibshirani, R.; Gu, S.G.; Fire, A.; Lui, W.-O. Ultra high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls. BMC Biol., 2010, 8, 58.
47. Rao, Q.; Zhou, H.; Peng, Y.; Li, J.; Lin, Z. Aberrant microRNA expression in human cervical carcinomas. Med. Oncol., 2012, 29, 1242-1248.
48. Zhang, Y.; Dai, Y.; Huang, Y.; Ma, L.; Yin, Y.; Tang, M.; Hu, C. Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus. J. Obstet. Gynaecol. Res., 2009, 35, 842-849.
49. Li, Y.; Wang, F.; Xu, J.; Ye, F.; Shen, Y.; Zhou, J.; Lu, W.; Wan, X.; Ma, D.; Xie, X. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J. Pathol., 2011, 224, 484-495.
50. Xu, X.-M.; Wang, X.-B.; Chen, M.-M.; Liu, T.; Li, Y.-X.; Jia, W.- H.; Liu, M.; Li, X.; Tang, H. MicroRNA-19a and-19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett., 2012, 322, 148-158.
51. Tsuchida, A.; Ohno, S.; Wu, W.; Borjigin, N.; Fujita, K.; Aoki, T.; Ueda, S.; Takanashi, M.; Kuroda, M. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci., 2011, 102, 2264-2271.
52. Kim, K.; Chadalapaka, G.; Lee, S.; Yamada, D.; Sastre-Garau, X.; Defossez, P.-A.; Park, Y.-Y.; Lee, J.-S.; Safe, S. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene, 2012, 31, 1034-1044.
53. Valladares-Ayerbes, M.; Blanco, M.; Haz, M.; Medina, V.; Iglesias- Diaz, P.; Lorenzo-Patino, M.J.; Reboredo, M.; Santamarina, I.; Figueroa, A.; Anton-Aparicio, L.M.; Calvo, L. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer. Int. J. Oncol., 2011, 39, 1253-1264.
54. Osada, H.; Takahashi, T. let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci., 2011, 102, 9-17.
55. Yu, J.; Ohuchida, K.; Mizumoto, K.; Fujita, H.; Nakata, K.; Tanaka, M. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol. Ther., 2010, 10, 748-757.
56. Kang, H.-W.; Wang, F.; Wei, Q.; Zhao, Y.-F.; Liu, M.; Li, X.; Tang, H. miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett., 2012, 586, 897-904.
57. Wei, Q.; Li, Y.X.; Liu, M.; Li, X.; Tang, H. MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells. IUBMB Life, 2012, 64, 697-704.
58. Huang, L.; Lin, J.-X.; Yu, Y.-H.; Zhang, M.-Y.; Wang, H.-Y.; Zheng, M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS ONE, 2012, 7, e33762.
59. Luo, M.; Shen, D.; Zhou, X.; Chen, X.; Wang, W. MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery, 2013, 153, 836-847.
60. Xu, Y.-Z.; Xi, Q.-H.; Ge, W.-L.; Zhang, X.-Q. Identification of Serum MicroRNA-21 as a Biomarker for Early Detection and Prognosis in Human Epithelial Ovarian Cancer. Asian Pac. J. Cancer Prev., 2013, 14, 1057-1060.
61. Toiyama, Y.; Takahashi, M.; Hur, K.; Nagasaka, T.; Tanaka, K.; Inoue, Y.; Kusunoki, M.; Boland, C.R.; Goel, A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl. Cancer Inst., 2013, 105, 849-859.
62. Kurashige, J.; Kamohara, H.; Watanabe, M.; Tanaka, Y.; Kinoshita, K.; Saito, S.; Hiyoshi, Y.; Iwatsuki, M.; Baba, Y.; Baba, H. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J. Surg. Oncol., 2012, 106, 188-192.
63. Zhao, S.; Yao, D.; Chen, J.; Ding, N. Circulating miRNA-20a and miRNA-203 for Screening Lymph Node Metastasis in Early Stage Cervical Cancer. Genet. Test. Mol. Biomarkers, 2013, 17, 631-636.
64. Pereira, P.M.; Marques, J.P.; Soares, A.R.; Carreto, L.; Santos, M.A. MicroRNA expression variability in human cervical tissues. PLoS ONE, 2010, 5, e11780.
65. Deftereos, G.; Corrie, S.R.; Feng, Q.; Morihara, J.; Stern, J.; Hawes, S.E.; Kiviat, N.B. Expression of mir-21 and mir-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS ONE, 2011, 6, e28423.
66. Yao, T.; Lin, Z. MiR-21 is involved in cervical squamous cell tumorigenesis and regulates CCL20. Biochim. Biophys. Acta, Mol. Basis Dis., 2012, 1822, 248-260.
67. Cheung, T.-h.; Man, K.-n.M.; Yu, M.-y.; Yim, S.-f.; Siu, N.S.; Lo, K.W.; Doran, G.; Wong, R.R.; Wang, V.W.; Smith, D.I. Dysregulated microRNAs in the pathogenesis and progression of cervical Neoplasm. Cell Cycle, 2012, 11, 2876-2884.
68. Martinez, I.; Gardiner, A.; Board, K.; Monzon, F.; Edwards, R.; Khan, S. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene, 2008, 27, 2575-2582.
69. Yamamoto, N.; Kinoshita, T.; Nohata, N.; Itesako, T.; Yoshino, H.; Enokida, H.; Nakagawa, M.; Shozu, M.; Seki, N. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int. J. Oncol., 2013, 42, 1523-1532.
70. Li, Y.; Liu, J.; Yuan, C.; Cui, B.; Zou, X.; Qiao, Y. High-risk human papillomavirus reduces the expression of microRNA-218 in women with cervical intraepithelial neoplasia. J. Int. Med. Res., 2010, 38, 1730-1736.
71. Bray, I.; Bryan, K.; Prenter, S.; Buckley, P.G.; Foley, N.H.; Murphy, D.M.; Alcock, L.; Mestdagh, P.; Vandesompele, J.; Speleman, F. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS ONE, 2009, 4, e7850.
72. Lionetti, M.; Agnelli, L.; Mosca, L.; Fabris, S.; Andronache, A.; Todoerti, K.; Ronchetti, D.; Deliliers, G.L.; Neri, A. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer, 2009, 48, 521-531.
73. Zhang, L.; Volinia, S.; Bonome, T.; Calin, G.A.; Greshock, J.; Yang, N.; Liu, C.-G.; Giannakakis, A.; Alexiou, P.; Hasegawa, K. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 7004-7009.
74. Tagawa, H.; Seto, M. A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia, 2005, 19, 2013-2016.
75. Zhang, Z.; Gerhard, D.S.; Nguyen, L.; Li, J.; Traugott, A.; Huettner, P.C.; Rader, J.S. Fine mapping and evaluation of candidate genes for cervical cancer on 11q23. Genes Chromosomes Cancer, 2005, 43, 95-103.
76. Heselmeyer, K.; Schröck, E.; Du Manoir, S.; Blegen, H.; Shah, K.; Steinbeck, R.; Auer, G.; Ried, T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 479-484.
77. Muralidhar, B.; Winder, D.; Murray, M.; Palmer, R.; Barbosa -Morais, N.; Saini, H.; Roberts, I.; Pett, M.; Coleman, N. Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles. J.Pathol., 2011, 224, 496-507.
78. Scotto, L.; Narayan, G.; Nandula, S.V.; Subramaniyam, S.; Kaufmann, A.M.; Wright, J.D.; Pothuri, B.; Mansukhani, M.; Schneider, A.; Arias-Pulido, H. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol. Cancer, 2008, 7, 58.
79. Muralidhar, B.; Goldstein, L.; Ng, G.; Winder, D.; Palmer, R.; Gooding, E.; Barbosa-Morais, N.; Mukherjee, G.; Thorne, N.; Roberts, I. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J. Pathol., 2007, 212, 368-377.
80. Nakamura, T.; Canaani, E.; Croce, C.M. Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 10980-10985.
81. Botezatu, A.; Goia-Rusanu, C.D.; Iancu, I.V.; Huica, I.; Plesa, A.; Socolov, D.; Ungureanu, C.; Anton, G. Quantitative analysis of the relationship between microRNA-124a,-34b and-203 gene methylation and cervical oncogenesis. Mol.Med.Rep., 2011, 4, 121-128.
82. Wilting, S.M.; van Boerdonk, R.A.; Henken, F.E.; Meijer, C.; Diosdado, B.; Meijer, G.A.; le Sage, C.; Agami, R.; Snijders, P.J.; Steenbergen, R.D. Research Methylation-mediated silencing and tumour suppressive function of hsamiR-124 in cervical cancer. Mol. Cancer, 2010, 9, 167.
83. Wilting, S.M.; Verlaat, W.; Jaspers, A.; Makazaji, N.A.; Agami, R.; Meijer, C.J.; Snijders, P.J.; Steenbergen, R.D. Methylation mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics, 2013, 8, 220-228.
84. Yao, T.; Rao, Q.; Liu, L.; Zheng, C.; Xie, Q.; Liang, J.; Lin, Z. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer. Virol. J., 2013, 10, 175.
85. Raghav, D.; Sharma, V.; Agarwal, S.M. Structural investigation of deleterious non-synonymous SNPs of EGFR gene. Interdiscip. Sci., 2013, 5, 60-68.
86. Ryan, B.M.; Robles, A.I.; Harris, C.C. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer, 2010, 10, 389-402.
87. Shi, T.-Y.; Chen, X.-J.; Zhu, M.-L.; Wang, M.-Y.; He, J.; Yu, K.- D.; Shao, Z.-M.; Sun, M.-H.; Zhou, X.-Y.; Cheng, X. A pri-miR- 218 variant and risk of cervical carcinoma in Chinese women. BMC Cancer, 2013, 13, 19.
88. Zhou, B.; Wang, K.; Wang, Y.; Xi, M.; Zhang, Z.; Song, Y.; Zhang, L. Common genetic polymorphisms in pre-microRNAs and risk of cervical squamous cell carcinoma. Mol. Carcinog., 2011, 50, 499-505.
89. Yue, C.; Wang, M.; Ding, B.; Wang, W.; Fu, S.; Zhou, D.; Zhang, Z.; Han, S. Polymorphism of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population. Gynecol. Oncol., 2011, 122, 33-37.
90. Reshmi, G.; Surya, R.; Jissa, V.; Babu, P.; Preethi, N.; Santhi, W.; Jayaprakash, P.; Pillai, M.R. C–T variant in a miRNA target site of BCL2 is associated with increased risk of human papilloma virus related cervical cancer—An in silico approach. Genomics, 2011, 98, 189-193.
91. Zhou, X.; Chen, X.; Hu, L.; Han, S.; Qiang, F.; Wu, Y.; Pan, L.; Shen, H.; Li, Y.; Hu, Z. Polymorphisms involved in the miR-218- LAMB3 pathway and susceptibility of cervical cancer, a case– control study in Chinese women. Gynecol. Oncol., 2010, 117, 287-290.
92. Srivastava, P.; Mangal, M.; Agarwal, S.M. Understanding the transcriptional regulation of cervix cancer using microarray gene expression data and promoter sequence analysis of a curated gene set. Gene, 2014, 535, 233-238.
93. Wang, J.; Lu, M.; Qiu, C.; Cui, Q. TransmiR: a transcription factormicroRNA regulation database. Nucleic Acids Res., 2010, 38, D119-122.
94. O'Donnell, K.A.; Wentzel, E.A.; Zeller, K.I.; Dang, C.V.; Mendell, J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 2005, 435, 839-843.
95. Wang, X.; Tang, S.; Le, S.-Y.; Lu, R.; Rader, J.S.; Meyers, C.; Zheng, Z.-M. Aberrant expression of oncogenic and tumorsuppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE, 2008, 3, e2557.
96. van Rooij, E. The art of microRNA research. Circ. Res., 2011, 108, 219-234.
97. Liu, B.; Li, J.; Cairns, M.J. Identifying miRNAs, targets and functions. Brief. Bioinform., 2012.
98. Liu, L.; Yu, X.; Guo, X.; Tian, Z.; Su, M.; Long, Y.; Huang, C.; Zhou, F.; Liu, M.; Wu, X. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol.Med.Rep., 2012, 5, 753-760.
99. Yao, Q.; Xu, H.; Zhang, Q.-Q.; Zhou, H.; Qu, L.-H. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem. Biophys. Res. Commun., 2009, 388, 539-542.
100. Yang, Z.; Chen, S.; Luan, X.; Li, Y.; Liu, M.; Li, X.; Liu, T.; Tang, H. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life, 2009, 61, 1075-1082.
101. Qiang, R.; Wang, F.; Shi, L.-Y.; Liu, M.; Chen, S.; Wan, H.-Y.; Li, Y.-X.; Li, X.; Gao, S.-Y.; Sun, B.-C.; Tang, H. Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int. J. Biochem. Cell Biol., 2011, 43, 632-641.
102. Peng, R.-Q.; Wan, H.-Y.; Li, H.-F.; Liu, M.; Li, X.; Tang, H. MicroRNA- 214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl---d-galactosamine: polypeptide N-acetylgalactosaminyltransferase 7. J. Biol. Chem., 2012, 287, 14301-14309.
103. Wang, F.; Liu, M.; Li, X.; Tang, H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett., 2013, 587, 488-495.
104. Pang, R.T.; Leung, C.O.; Ye, T.-M.; Liu, W.; Chiu, P.C.; Lam, K.K.; Lee, K.-F.; Yeung, W.S. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis, 2010, 31, 1037-1044.
105. Wang, X.; Meyers, C.; Guo, M.; Zheng, Z.M. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int. J. Cancer, 2011, 129, 1362-1372.
106. Xie, H.; Zhao, Y.; Caramuta, S.; Larsson, C.; Lui, W.-O. miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS ONE, 2012, 7, e46990.
107. Li, B.H.; Zhou, J.S.; Ye, F.; Cheng, X.D.; Zhou, C.Y.; Lu, W.G.; Xie, X. Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur. J. Cancer, 2011, 47, 2166-2174.
108. Yeung, C.A.; Tsang, T.; Yau, P.; Kwok, T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene, 2011, 30, 2401-2410.
109. Long, M.-J.; Wu, F.-X.; Li, P.; Liu, M.; Li, X.; Tang, H. MicroRNA- 10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett., 2012, 324, 186-196.
110. Wang, F.; Li, Y.; Zhou, J.; Xu, J.; Peng, C.; Ye, F.; Shen, Y.; Lu, W.; Wan, X.; Xie, X. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am. J. Pathol., 2011, 179, 2580-2588.
111. Li, J.-H.; Xiao, X.; Zhang, Y.-N.; Wang, Y.-M.; Feng, L.-M.; Wu, Y.-M.; Zhang, Y.-X. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol. Oncol., 2011, 120, 145-151.
112. Tian, R.-Q.; Wang, X.-H.; Hou, L.-J.; Jia, W.-H.; Yang, Q.; Li, Y.- X.; Liu, M.; Li, X.; Tang, H. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J. Biol. Chem., 2011, 286, 25556-25563.
113. Qin, W.; Dong, P.; Ma, C.; Mitchelson, K.; Deng, T.; Zhang, L.; Sun, Y.; Feng, X.; Ding, Y.; Lu, X. MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene, 2012, 31, 4067-4075.
114. Xu, J.; Li, Y.; Wang, F.; Wang, X.; Cheng, B.; Ye, F.; Xie, X.; Zhou, C.; Lu, W. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene, 2013, 32, 976-987.
115. Wu, L.; Li, H.; Jia, C.Y.; Cheng, W.; Yu, M.; Peng, M.; Zhu, Y.; Zhao, Q.; Dong, Y.W.; Shao, K. MicroRNA-223 regulates FOXO1 expression and cell proliferation. FEBS Lett., 2012, 586, 1038-1043.
116. Cui, F.; Li, X.; Zhu, X.; Huang, L.; Huang, Y.; Mao, C.; Yan, Q.; Zhu, J.; Zhao, W.; Shi, H. MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta. Cell. Physiol. Biochem., 2012, 30, 1310-1318.
117. Lei, C.; Wang, Y.; Huang, Y.; Yu, H.; Huang, Y.; Wu, L.; Huang, L. Up-regulated miR155 Reverses the Epithelial-mesenchymal Transition Induced by EGF and Increases Chemo-sensitivity to Cisplatin in Human Caski Cervical Cancer Cells. PLoS ONE, 2012, 7, e52310.
118. Tang, T.; Wong, H.K.; Gu, W.; Yu, M.-y.; To, K.-F.; Wang, C.C.; Wong, Y.F.; Cheung, T.H.; Chung, T.K.H.; Choy, K.W. MicroRNA- 182 plays an onco-miRNA role in cervical cancer. Gynecol. Oncol., 2013, 129, 199-208.
119. Shi, M.; Du, L.; Liu, D.; Qian, L.; Hu, M.; Yu, M.; Yang, Z.; Zhao, M.; Chen, C.; Guo, L. Glucocorticoid regulation of a novel HPV– E6–p53–miR–145 pathway modulates invasion and therapy resistance of cervical cancer cells. J.Pathol., 2012, 228, 148-157.
120. Wu, X.; Xiao, H. miRNAs modulate the drug response of tumor cells. Sci. China C Life Sci., 2009, 52, 797-801.
121. Brewer, C.A.; Blessing, J.A.; Nagourney, R.A.; McMeekin, D.S.; Lele, S.; Zweizig, S.L. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol., 2006, 100, 385-388.
122. Nagai, Y.; Toita, T.; Wakayama, A.; Nakamoto, T.; Ooyama, T.; Tokura, A.; Inamine, M.; Kudaka, W.; Murayama, S.; Aoki, Y. Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix. Anticancer Res., 2012, 32, 1475-1479.
123. Liu, J.; Yang, L.; Zhang, J.; Zhang, J.; Chen, Y.; Li, K.; Li, Y.; Li, Y.; Yao, L.; Guo, G. Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. BMC Cancer, 2012, 12, 370.
124. Li, J.; Ping, Z.; Ning, H. MiR-218 Impairs Tumor Growth and Increases Chemo-Sensitivity to Cisplatin in Cervical Cancer. Int. J. Mol. Sci., 2012, 13, 16053-16064.
125. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31, 1869-1883.
126. Yu, J.; Ryan, D.G.; Getsios, S.; Oliveira-Fernandes, M.; Fatima, A.; Lavker, R.M. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 19300-19305.
127. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111.
128. Xu, P.; Vernooy, S.Y.; Guo, M.; Hay, B.A. The Drosophila MicroRNA Mir-14 Suppresses Cell Death and Is Required for Normal Fat Metabolism. Curr. Biol., 2003, 13, 790-795.
129. Antonsson, B.; Martinou, J.-C. The Bcl-2 protein family.Exp. Cell Res., 2000, 256, 50-57.
130. Green, D.R.; Chipuk, J.E. Apoptosis: stabbed in the BAX. Nature, 2008, 455, 1047-1049.
131. Uesugi, A.; Kozaki, K.-I.; Tsuruta, T.; Furuta, M.; Morita, K.-i.; Imoto, I.; Omura, K.; Inazawa, J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res., 2011, 71, 5765-5778.
132. Coulthard, L.R.; White, D.E.; Jones, D.L.; McDermott, M.F.; Burchill, S.A. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol. Med., 2009, 15, 369-379.
133. Evan, G.I.; Vousden, K.H. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411, 342-348.
134. Baldwin, A.; Li, W.; Grace, M.; Pearlberg, J.; Harlow, E.; Münger, K.; Grueneberg, D.A. Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 16478-16483.
135. Seki, E.; Brenner, D.A.; Karin, M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology, 2012, 143, 307-320.
136. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 2009, 9, 153-166.
137. Arora, A.; Gera, S.; Maheshwari, T.; Raghav, D.; Alam, M.J.; Singh, R.K.; Agarwal, S.M. The dynamics of stress p53-Mdm2 network regulated by p300 and HDAC1. PLoS ONE, 2013, 8, e52736.
138. Alam, M.J.; Devi, G.R.; Ravins; Ishrat, R.; Agarwal, S.M.; Singh, R.K. Switching p53 states by calcium: dynamics and interaction of stress systems. Mol. BioSyst., 2013, 9, 508-521.
139. Castellano, G.; Torrisi, E.; Ligresti, G.; Malaponte, G.; Militello, L.; Russo, A.E.; McCubrey, J.A.; Canevari, S.; Libra, M. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle, 2009, 8, 1367-1372.
140. He, G.; Wang, Q.; Zhou, Y.; Wu, X.; Wang, L.; Duru, N.; Kong, X.; Zhang, P.; Wan, B.; Sui, L. YY1 is a novel potential therapeutic target for treatment of HPV-infection induced cervical cancer by arsenic trioxide. Int. J. Gynecol. Cancer, 2011, 21, 1097-1104.
141. Wei SZL.; Efferth, T. Polo-like kinase 1 as target for cancer therapy. Exp. Hematol. Oncol., 2012, 1, 38.
142. Dhar, A.; Ray, A. The CCN family proteins in carcinogenesis. Exp. Oncol., 2010, 32, 2-9.
143. Radisky, E.S.; Radisky, D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia, 2010, 15, 201-212.
144. Dass, K.; Ahmad, A.; Azmi, A.S.; Sarkar, S.H.; Sarkar, F.H. Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev., 2008, 34, 122-136.
145. Samouelian, V.; Revillion, F.; Alloy, N.; Lhotellier, V.; Leblanc, E.; Peyrat, J. Measurement of mRNA of 11 biomarkers by RT-PCR to detect lymph node involvement in cervical cancer. Int. J. Biol. Markers, 2008, 23, 74-82.
146. Salvi, A.; Sabelli, C.; Moncini, S.; Venturin, M.; Arici, B.; Riva, P.; Portolani, N.; Giulini, S.M.; De Petro, G.; Barlati, S. MicroRNA- 23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J., 2009, 276, 2966-2982.
147. Whitley, B.R.; Palmieri, D.; Twerdi, C.D.; Church, F.C. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp. Cell Res., 2004, 296, 151-162.
148. Yang, H.-S.; Matthews, C.P.; Clair, T.; Wang, Q.; Baker, A.R.; Li, C.-C.H.; Tan, T.-H.; Colburn, N.H. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol. Cell. Biol., 2006, 26, 1297-1306.
149. Benbow, U.; Brinckerhoff, C.E. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol., 1997, 15, 519-526.
150. Hakomori, S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 10231-10233.
151. Tamagnone, L.; Artigiani, S.; Chen, H.; He, Z.; Ming, G.-l.; Song, H.-j.; Chedotal, A.; Winberg, M.L.; Goodman, C.S.; Poo, M.-M. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell, 1999, 99, 71-80.
152. Vikis, H.G.; Li, W.; Guan, K.-L. The plexin-B1/Rac interaction inhibits PAK activation and enhances Sema4D ligand binding. Genes Dev., 2002, 16, 836-845.
153. Swiercz, J.M.; Kuner, R.; Offermanns, S. Plexin-B1/RhoGEF– mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. J. Cell Biol., 2004, 165, 869-880.
154. Guess, C.M.; Quaranta, V. Defining the role of laminin-332 in carcinoma. Matrix Biol., 2009, 28, 445-455.
155. Marinkovich, M.P. Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat. Rev. Cancer, 2007, 7, 370-380.
156. Skyldberg, B.; Salo, S.; Eriksson, E.; Aspenblad, U.; Moberger, B.; Tryggvason, K.; Auer, G. Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl. Cancer Inst., 1999, 91, 1882-1887.
157. Carter, W.G.; Ryan, M.C.; Gahr, P.J. Epiligrin, a new cell adhesion ligand for integrin -3-1 in epithelial basement membranes. Cell, 1991, 65, 599-610.
158. Schenk, S.; Hintermann, E.; Bilban, M.; Koshikawa, N.; Hojilla, C.; Khokha, R.; Quaranta, V. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J. Cell Biol., 2003, 161, 197-209.
159. Okamoto, O.; Bachy, S.; Odenthal, U.; Bernaud, J.; Rigal, D.; Lortat- Jacob, H.; Smyth, N.; Rousselle, P. Normal human keratinocytes bind to the -3LG4/5 domain of unprocessed laminin-5 through the receptor syndecan-1. J. Biol. Chem., 2003, 278, 44168-44177.
160. Mizejewski, G.J. Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med., 1999, 222, 124-138.
161. Suárez, Y.; Sessa, W.C. MicroRNAs as novel regulators of angiogenesis. Circ. Res., 2009, 104, 442-454.
162. Milanini-Mongiat, J.; Pouysségur, J.; Pagès, G. Identification of Two Sp1 Phosphorylation Sites for p42/p44 Mitogen-activated Protein Kinases: their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem., 2002, 277, 20631-20639.
163. Nikolic, I.; Plate, K.-H.; Schmidt, M.H. EGFL7 meets miRNA- 126: an angiogenesis alliance. J. Angiogenes Res., 2010, 2, 9.